CURRENT ISSUE

Volume-IX

, Issue-II

(SPRING 2024)



01 - Evaluating Poly-Pharmacy and Drug Interactions in Cardiovascular Treatment: A Ca...

http://dx.doi.org/10.31703/gpsr.2024(IX-II).01
10.31703/gpsr.2024(IX-II).01      Published : Jun 2024

    Drug-drug interactions (DDIs) have a considerable impact on therapeutic response which, in turn, could result in adverse drug reactions (ADRs), or even treatment failure. It was directed at patients with cardiovascular diseases (CVDs) as this patient group is more likely to experience DDIs owing to the complexity and number of their drug treatments. The study, analyzed 108 prescriptions using diff... Details
    Cardiovascular Diseases, Drug-drug Interactions (DDI’s), Poly-pharmacy
    (1) Muhammad Adnan
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
    (2) Savera Saghir
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
    (3) Ejaz Ahmed
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
    (4) Aimen Sahar
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
    (5) Ahmad Jalal Masood
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.

02 - Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approach...

http://dx.doi.org/10.31703/gpsr.2024(IX-II).02
10.31703/gpsr.2024(IX-II).02      Published : Jun 2024

    Immunotherapy is a medical intervention in which certain immune system components are used to combat disease. Usually, immunotherapy works by helping the body fight off the offending substance by modifying it as well as boosting the immune system. Biologic therapy or biotherapy are additional terms for certain forms of immunotherapy. Different advances and novel approaches have been studied such a... Details
    Cancer, ADCs, Immunotherapeutic, Oral Immunotherapeutic, Combination Therapies, Targeted Therapies, Adverse Effects, Challenges, Advancement in Immunotherapy
    (1) Kalya Ahmad Sandhu
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
    (2) Asawar Yameen
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
    (3) Naima Zafar
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
    (4) Hira Ali
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
    (5) Usama Abid
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
    (6) Mishkaat Raza
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.

03 - Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next G...

http://dx.doi.org/10.31703/gpsr.2024(IX-II).03
10.31703/gpsr.2024(IX-II).03      Published : Jun 2024

    This review focuses on the physicochemical properties of nanocarriers (NCs) and the physical properties of the tumor microenvironment (TME), highlighting strategies used to specifically deliver molecules of interest to specific lesions. This review discusses these products, explains the simple selection of high-performance and active methods, and illustrates this with examples of drugs that are fo... Details
    NP (nanoparticles), EPR (Enhanced permeation and retention), TME (tumor microenvironment), MDR (multiple drug resistance), HCC (hepatic cell carcinoma), SDDS (Smart Drug Delivery Systems)
    (1) Dua Zahid
    Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.
    (2) Rabia Tahir
    Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.
    (3) Wajiha Ashfaq
    Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.
    (4) Abdul Wasay
    Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.
    (5) Qamer Iqbal
    Graduate at Saulat Institute of Pharmaceuticals Sciences, QAU, Islamabad, Pakistan.

04 - Analyzing Euglycemic Diabetic Ketoacidosis Trends Amidst the Rise of SGLT-2 Inhi...

http://dx.doi.org/10.31703/gpsr.2024(IX-II).04
10.31703/gpsr.2024(IX-II).04      Published : Jun 2024

    This overview investigates the increasing prevalence of sodium-glucose cotransporter-2 (SGLT-2) inhibitor-associated euglycemic diabetic ketoacidosis (EDKA) in type II diabetes patients. Due to its tendency to occur with normal or somewhat high blood sugar levels, EDKA poses unique obstacles to diagnosis and treatment. Based on an extensive review of recent literature, we examine clinical motifs, ... Details
    DKA, Euglycemic Diabetic Ketoacidosis (EDKA), SGLT-2 Inhibitors, Type II Diabetes, Patient Education
    (1) Muhammad Adnan
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
    (2) Ejaz Ahmed
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
    (3) Aimen Sahar
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
    (4) Savera Saghir
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
    (5) Mohammad Hossein Rafieikia
    Graduate, Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University Islamabad, Pakistan.
    (6) Ahtasham Saleem
    Graduate, Bioscience Department, COMSATS University Islamabad, Pakistan.